OLVIG
BIIB icon

Oliver Lagore Vanvalin Investment Group’s Biogen BIIB Stock Holding History

Oliver Lagore Vanvalin Investment Group’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-24
Closed -$6.67K – 785
2023
Q1 		$6.67K Sell
24
-2
-8% -$553 ﹤0.01% 445
2022
Q4 		$7.2K Buy
+26
New +$7.34K ﹤0.01% 414

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Oliver Lagore Vanvalin Investment Group's BIIB Position: Q2 2023 in Review

Oliver Lagore Vanvalin Investment Group sold out of Biogen (BIIB) in Q2 2023, closing a stake of 24 shares — an estimated $6.67K sold.

Oliver Lagore Vanvalin Investment Group first reported a position in BIIB in Q4 2022 and held it in 2 quarters. The position peaked at $7.2K in Q4 2022. 1,008 funds tracked by Wall St. Rank hold BIIB as of Q2 2023.

  • Oliver Lagore Vanvalin Investment Group reported no remaining Biogen position as of Q2 2023 after selling out during the quarter.
  • Oliver Lagore Vanvalin Investment Group sold 24 Biogen shares in Q2 2023, an estimated $6.67K.
  • Oliver Lagore Vanvalin Investment Group first reported a position in Biogen in Q4 2022 and held it in 2 quarters.
  • Oliver Lagore Vanvalin Investment Group's Biogen position peaked at $7.2K in Q4 2022.
  • 1,008 funds tracked by Wall St. Rank held Biogen as of Q2 2023.

Based on Oliver Lagore Vanvalin Investment Group's 13F filing for Q2 2023, filed 8 Aug 2023.